NCT00438061|CompletedPhase 3
Effect of Abdominal Obesity on Lipoprotein Metabolism
Effect of Weight Loss on Lipoprotein Metabolism in Abdominal Obesity
Loading search results
Effect of Weight Loss on Lipoprotein Metabolism in Abdominal Obesity
Sponsor study identifier
interventional
40
1 country
1
Study Start
January 1995
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
December 1998
Date type not reportedThis date has not been verified as actual or estimated.
Abdominal obesity is strongly associated with dyslipidemia, which may account for the associated increased risk of atherosclerosis and coronary disease. Weight reduction is suggested to be a preferred and effective first-line strategy to correct lipid abnormalities, particularly in overweight/obese subjects. This improvement may be related to the effect of reduction in abdominal fat mass on apoB and apoA-I metabolism, but this remains to be fully demonstrated. Hypothesis: Reduction in abdominal fat mass by weight loss decreases apoB concentration and raises HDL-cholesterol chiefly by increasing LDL-apoB fractional catabolic rate (FCR), as well as decreasing HDL apoA-I, respectively.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 1998
Date type not reportedThis date has not been verified as actual or estimated.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 1995
Date type not reportedThis date has not been verified as actual or estimated.
December 1998
Date type not reportedThis date has not been verified as actual or estimated.
February 20, 2007
Actual (reported)February 21, 2007
Actual (reported)Primary: Fractional catabolic and production rates of LDL-apoB and HDL-apoA-I (before and after 16 week treatments)
Secondary: Cholesterol; Triglyceride; LDL-cholesterol; Adipocytokines; Genetic polymorphism
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Royal Perth Hospital
Perth, Western Australia, 6000, Australia
Dick C Chan, PhD
The University of Western Australia
Gerald F Watts, MD
The University of Western Australia
First Submitted
February 20, 2007
First Posted
February 21, 2007
Study Start
January 1995
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
December 1998
Date type not reportedDyslipidemia of Obesity Intervention in Teens
Contact the study team to confirm eligibility.
This date has not been verified as actual or estimated.
Last Updated
February 26, 2007
Record last verified: 2007-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: